Health Care • Biotechnology: Pharmaceutical Preparations
$0.88 ▲ +0.05
(+5.73%)
MKT CAP: $20.0M • VOL: 6.85M
52W L $0 52W H $11
ROARABLE / RQD
D • 47/100
PIOTROSKI
2 / 9
KPTI // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $146.1M | $145.2M | $146.0M |
| YoY Revenue Growth % | +0.6% | -0.5% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$90.7M | -$119.4M | -$129.5M |
| Operating Margin % | -62.1% | -80.0% | -80.0% |
| Net Income (GAAP) | -$196.0M | -$76.4M | -$143.1M |
| EBITDA (Normalized) | -$90.7M | -$119.3M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$75.4M | -$127.5M | -$92.7M |
| Capital Expenditures (CapEx) | $0 | $142.0K | — |
| Free Cash Flow (FCF) | -$75.4M | -$127.6M | -$92.7M |
| FCF Margin % | -51.6% | -80.0% | -63.5% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $60.5M | $62.5M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | -$292.9M | -$186.0M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR KPTI.